Trump Victory To Breathe Life Into Korean Biopharmas?
Executive Summary
South Korean analysts and pharma firms are generally viewing Donald Trump's win in the US presidential election as positive for the sector, which is stepping up efforts to enter global markets including the US.
You may also be interested in...
Celltrion’s Biosimilar Rituximab Edges Ahead With Korean Approval
Celltrion has edged ahead of its competitors in the close race to develop biosimilar versions of rituximab with the approval of its product in South Korea, which could help speed development in other markets where the South Korean firm is also seeking approvals.
Celltrion’s Biosimilar Rituximab Edges Ahead With Korean Approval
Celltrion has edged ahead of its competitors in the close race to develop biosimilar versions of rituximab with the approval of its product in South Korea, which could help speed development in other markets where the South Korean firm is also seeking approvals.
Will 'Businessman' Trump See The Value In Indian Generics?
The election of Donald Trump as the next US president might suggest a degree of policy unpredictability for pharma companies but Indian firms are hoping that the businessman in the real estate mogul and President-elect will see the value that generics offer.